Scarica l'app Stockscreener
2.60
0.19%
0.005
Dopo l'orario di chiusura:
2.57
-0.03
-1.15%
Precedente Chiudi:
$2.595
Aprire:
$2.64
Volume 24 ore:
30,096
Relative Volume:
0.57
Capitalizzazione di mercato:
$223.06M
Reddito:
-
Utile/perdita netta:
$-29.64M
Rapporto P/E:
-6.0465
EPS:
-0.43
Flusso di cassa netto:
$-39.43M
1 W Prestazione:
-1.52%
1M Prestazione:
+3.17%
6M Prestazione:
+14.04%
1 anno Prestazione:
+4.42%
Intervallo 1D:
$2.57
$2.64
Intervallo di 1 settimana:
$2.50
$2.74
Portata 52W:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Nome
Alpha Tau Medical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta DRTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.60 | 223.06M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-04-24 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Iniziato | Piper Sandler | Overweight |
| 2022-04-04 | Iniziato | Citigroup | Buy |
Alpha Tau Medical Ltd Borsa (DRTS) Ultime notizie
Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Lifts Earnings Estimates for Alpha Tau Medical - Defense World
Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering - Latham & Watkins LLP
Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating - TipRanks
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Medical (DRTS) Secures $36.9M in Strategic Stock Sale - GuruFocus
Oramed Invests in Alpha Tau (DRTS) with Strategic Partnership | - GuruFocus
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - marketscreener.com
Alpha Tau enters strategic marketing alliance with Oramed - TipRanks
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau Medical (NASDAQ:DRTSW) Shares Up 2.3% – Still a Buy? - Defense World
Comparing ICU Medical (NASDAQ:ICUI) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
High Intensity Focused Ultrasound (HIFU) Market to Witness - openPR.com
Alpha Emitter Market to Witness Massive Growth by 2032 | Actinium - openPR.com
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer - Curetoday
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 7.4% – Time to Sell? - Defense World
Alpha Tau Receives Fda Approval to Initiate A Trial for Patients with Recurrent Glioblastoma - MarketScreener
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM - TipRanks
Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma - MarketScreener
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma - GlobeNewswire
Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Comprehensive Insights of the Global Vulvar Cancer Market: Key Drivers, Trends, Growth Opportunities, and F... - WhaTech
Pancreatic Ductal Adenocarcinoma Pipeline: Shaping the Future - openPR.com
Alpha Emitter Market Demand, Growth and Future Scope 2025-2032 | - openPR
HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical - Defense World
Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment - openPR.com
Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - The Globe and Mail
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target - Investing.com
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target By Investing.com - Investing.com UK
Promising Clinical and Regulatory Milestones Drive Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau's Cancer Therapy Achieves 100% Disease Control Rate in Latest Trials - StockTitan
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
U.S. Brain Tumor Market Size & Share | Industry Report 2034 - Grand View Research
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment - Targeted Oncology
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts - TipRanks
Alpha Tau Medical Ltd Azioni (DRTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):